Theroux, P., Armstrong, P. W., Mahaffey, K. W., Hochman, J. S., Rollins, S., Malloy, K. J., … Granger, C. B. (2004). 833-5 Markers of inflammation predict mortality and are reduced by pexelizumab in patients with acute myocardial infarction: Insights from the complement inhibition in myocardial infarction treated with angioplasty (COMMA) trial. In Journal of the American College of Cardiology (Vol. 43, pp. A287–A287). Elsevier BV. https://doi.org/10.1016/s0735-1097(04)91216-8

Theroux, Pierre, Paul W. Armstrong, Kenneth W. Mahaffey, Judith S. Hochman, Scott Rollins, Kevin J. Malloy, Thomas Parish, Jose C. Nicolau, Joel Lavoie, and Christopher B. Granger. “833-5 Markers of inflammation predict mortality and are reduced by pexelizumab in patients with acute myocardial infarction: Insights from the complement inhibition in myocardial infarction treated with angioplasty (COMMA) trial.” In Journal of the American College of Cardiology, 43:A287–A287. Elsevier BV, 2004. https://doi.org/10.1016/s0735-1097(04)91216-8.

Theroux P, Armstrong PW, Mahaffey KW, Hochman JS, Rollins S, Malloy KJ, et al. 833-5 Markers of inflammation predict mortality and are reduced by pexelizumab in patients with acute myocardial infarction: Insights from the complement inhibition in myocardial infarction treated with angioplasty (COMMA) trial. In: Journal of the American College of Cardiology. Elsevier BV; 2004. p. A287–A287.

Theroux, Pierre, et al. “833-5 Markers of inflammation predict mortality and are reduced by pexelizumab in patients with acute myocardial infarction: Insights from the complement inhibition in myocardial infarction treated with angioplasty (COMMA) trial.” Journal of the American College of Cardiology, vol. 43, no. 5, Elsevier BV, 2004, pp. A287–A287. Crossref, doi:10.1016/s0735-1097(04)91216-8.

Theroux P, Armstrong PW, Mahaffey KW, Hochman JS, Rollins S, Malloy KJ, Parish T, Nicolau JC, Lavoie J, Granger CB. 833-5 Markers of inflammation predict mortality and are reduced by pexelizumab in patients with acute myocardial infarction: Insights from the complement inhibition in myocardial infarction treated with angioplasty (COMMA) trial. Journal of the American College of Cardiology. Elsevier BV; 2004. p. A287–A287.